Research & Development

Basecamp Research secures $140m for AI-driven therapies

UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development.

BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.

Superluminal Medicines secures $60m to advance rare obesity therapy

US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.

Takeda and Weave Bio collaborate on AI-driven automation in drug development

Takeda has entered a collaboration to introduce Weave Bio’s AI-native regulatory automation platform across 14 ongoing drug development programmes in various global markets.

WellSpan and Johns Hopkins renew partnership for advanced cancer care access

WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.

SandboxAQ introduces AQPotency for virtual drug screening

US-based SandboxAQ has introduced AQPotency, a Large Quantitative Model (LQM) designed to virtually screen and predict the potential of drug candidates without the need for a solved protein structure.

Xanadu and University of Alberta to develop quantum algorithms for cancer

Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to treat cancer.

Innovent and Daiichi Sankyo sign deal for Vanflyta in China

Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.

Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs

Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku for its investigational topical drug ENERGI-F703DFU to treat diabetic foot ulcers (DFUs).